{"id":"copper-histidinate","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":{"setId":"e3aeefc2-f44d-4337-9c2e-3dba44a89e48","title":"ZYCUBO (COPPER HISTIDINATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [SENTYNL THERAPEUTICS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Copper is an essential trace element required for multiple enzymatic processes including cytochrome c oxidase, lysyl oxidase, and superoxide dismutase. Copper histidinate is a chelate complex that enhances copper absorption in the gastrointestinal tract, allowing systemic copper repletion in patients who cannot adequately absorb dietary copper due to genetic disorders or malabsorption conditions.","oneSentence":"Copper histidinate provides bioavailable copper to restore deficient copper levels in patients with copper malabsorption or deficiency.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:28:58.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Copper deficiency due to malabsorption (including Menkes disease and related copper transport disorders)"}]},"trialDetails":[{"nctId":"NCT04074512","phase":"","title":"Copper Histidinate Treatment for Menkes Disease","status":"APPROVED_FOR_MARKETING","sponsor":"Sentynl Therapeutics, Inc.","startDate":"","conditions":"Menkes Disease","enrollment":""},{"nctId":"NCT04337684","phase":"","title":"Long Term Follow-up on Menkes Disease Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sentynl Therapeutics, Inc.","startDate":"2019-12-01","conditions":"Menkes Disease","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CUTX-101"],"phase":"marketed","status":"active","brandName":"copper histidinate","genericName":"copper histidinate","companyName":"Sentynl Therapeutics, Inc.","companyId":"sentynl-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Copper histidinate provides bioavailable copper to restore deficient copper levels in patients with copper malabsorption or deficiency. Used for Copper deficiency due to malabsorption (including Menkes disease and related copper transport disorders).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}